Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avigen Inc.
Gene transfer of decarboxylase protects striatal cultures from L-DOPA
June 22nd, 2005
Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity. "Although L-DOPA is the drug of choice for Parkinson disease, prolonged L-DOPA therapy results in decreased drug effectiveness and the appearance of motor complications. This may be due in part to the progressive loss of the enzyme, aromatic L-amino acid decarboxylase (AADC). We have developed an adeno-associated virus vector (AAV-hAADC) that contains human AADC cDNA under the control of the cytomegalovirus promoter. Infusion of this vector into the striatum of parkinsonian rats and monkeys improves L-DOPA...
Source: Physician Law Weekly (2005-06-22)
|
